• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides compositions, methods and methods for the processing of submicron liposomal compositions comprising a lipid, a sterol, and a saponin.
    公开号:BE1025160B1
    申请号:E2017/5901
    申请日:2017-12-05
    公开日:2018-11-26
    发明作者:Véronique Monique Roberte Henderickx；Philippe Cara；Cupere Vinciane Martha De；Kesel Carine Berthe Ghislaine De
    申请人:Glaxosmithkline Biologicals Sa；
    IPC主号:
    专利说明:

    (30) Priority data:
    12/07/2016 GB 1620758.1
    06/01/2017 GB 1708734.7 (73) Holder (s):
    GLAXOSMITHKLINE BIOLOGICALS SA 1330, RIXENSART
    Belgium (72) Inventor (s):
    CARA Philippe
    1330 RIXENSART
    Belgium
    HENDERICKX Véronique Monique Roberte
    1330 RIXENSART
    Belgium
    FROM CUPERE Vinciane Martha
    1330 RIXENSART
    Belgium
    BY KESEL Carine Berthe Ghislaine
    1330 RIXENSART
    Belgium (54) NEW PROCESS (57) The present invention provides compositions, methods and methods for the maturation of submicronic liposomal compositions comprising a lipid, a sterol, and a saponin.
    Water for injectables q.s.p. 0.5 ml I
    Phosphate buffer Na / K 100 mM PO 4 3 'qs 10 mM POy
    I
    1500 mM NaCI
    q.s.p. 150 mM NaCI
    I
    Agitation 15 at T5 min at TA 1
    Concentrated liposomal mass at 2000 pg of MPlÇml
    I
    Agitation 15 to 45 min at RT
    I
    Add QS21 to 5000 pg / ml 1 Agitation 15 to 45 min at RT
    I Maturation
    I
    Agitation 15 to 20 min
    I pH adjustment
    I
    Sterilization by filtration
    I
    Storage at 2 to 8 ° C
    BELGIAN INVENTION PATENT
    FPS Economy, SMEs, Middle Classes & Energy Publication number: 1025160Filing number: BE2017 / 5901 Intellectual Property Office International Classification: A61K 39/04 A61K 9/127 A61K 47/28A61K 31/706 A61K 39/39 A61K 45/06 A61K 31/7032Issue date: 11/26/2018
    The Minister of the Economy,
    Having regard to the Paris Convention of March 20, 1883 for the Protection of Industrial Property;
    Considering the law of March 28, 1984 on patents for invention, article 22, for patent applications introduced before September 22, 2014;
    Given Title 1 “Patents for invention” of Book XI of the Code of Economic Law, article XI.24, for patent applications introduced from September 22, 2014;
    Having regard to the Royal Decree of 2 December 1986 relating to the request, the issue and the maintenance in force of invention patents, article 28;
    Given the patent application received by the Intellectual Property Office on 05/12/2017.
    Whereas for patent applications falling within the scope of Title 1, Book XI of the Code of Economic Law (hereinafter CDE), in accordance with article XI. 19, §4, paragraph 2, of the CDE, if the patent application has been the subject of a search report mentioning a lack of unity of invention within the meaning of the §ler of article XI.19 cited above and in the event that the applicant does not limit or file a divisional application in accordance with the results of the search report, the granted patent will be limited to the claims for which the search report has been drawn up.
    Stopped :
    First article. - It is issued to
    GLAXOSMITHKLINE BIOLOGICALS SA, Rue de l'arstitut 89, 1330 RIXENSART Belgium;
    represented by
    PRONOVEM - Office Van Malderen, Avenue Josse Goffin 158, 1082, BRUXELLES;
    a 20-year Belgian invention patent, subject to the payment of the annual fees referred to in article XI.48, §1 of the Code of Economic Law, for: NEW PROCESS.
    INVENTOR (S):
    CARA Philippe, c / o GlaxoSmithKline Biologicals SA, Rue de l'institut 89, 1330, RIXENSART;
    HENDERICKX Véronique Monique Roberte, c / o GlaxoSmithKline Biologicals SA, Rue de l'institut 89, 1330, RIXENSART;
    DE CUPERE Vinciane Martha, c / o GlaxoSmithKline Biologicals SA, Rue de l'institut 89, 1330, RIXENSART;
    DE KESEL Carine Berthe Ghislaine, c / o GlaxoSmithKline Biologicals SA, Rue de l'institut 89, 1330, RIXENSART;
    PRIORITY (S):
    12/07/2016 GB 1620758.1;
    06/01/2017 GB 1708734.7;
    DIVISION:
    divided from the basic request:
    filing date of the basic application:
    Article 2. - This patent is granted without prior examination of the patentability of the invention, without guarantee of the merit of the invention or of the accuracy of the description thereof and at the risk and peril of the applicant (s) ( s).
    Brussels, 11/26/2018,
    By special delegation:
    BE2017 / 5901
    NEW PROCESS
    Technical area
    The present invention relates to improved methods for the production of liposomal compositions containing saponins, in particular the filtration of such compositions.
    1 rnventron background
    In recent decades, liposomes (also known as a vesicle increasingly used for pharmaceutical compounds. The multiple lipid bilayers lipid bilayers) have been encapsulate and administer liposomes include one or (such as phospholipids) and may contain d other molecules, such as proteins or carbohydrates, in their structure. The lipid layer on the liposome confines and protects the encapsulated pharmaceutical compound until the liposome reaches its destination and adheres to the outer membrane of the target cells. By this method, the toxicity of a drug to healthy cells is minimized and the therapeutic efficacy can be increased. Thanks to the presence of the two lipid and aqueous phases in their structure, the liposomes can be used in the encapsulation or the imprisonment of water-soluble, liposoluble and amphiphilic material.
    BE2017 / 5901
    The liposomes can be used in vaccine / immunogenic compositions for the formulation of adjuvant compositions.
    As these adjuvant compositions are often administered parenterally to humans, it is desirable that they be sterile. The liposomes used as adjuvants are generally submicron liposomes and they are small enough to be sterilized by filtration through filters.
    0.2 μm.
    It is an object of the present invention to provide an improved filtration method for submicron liposomes.
    Summary of the invention
    The present inventors have improved the filtration of submicron liposomes containing saponins using methods involving the maturation of submicron liposomal formulations. Therefore, the present invention provides a process for manufacturing a composition comprising a saponin in a submicron liposomal formulation, comprising the following steps:
    at. the preparation of a first submicron liposomal formulation in which the liposomes contain a lipid and a sterol,
    b. adding saponin to the first submicron liposomal formulation,
    vs. the maturation of the submicron liposomal formulation containing the saponin for at least 1, at least 2,
    at least 3, at least 4, at less 5, at least 6, at less 7, at minus 8, at least 9, at least 10, at least 11, at less 12, at least 13, at less 14, at least 15, or, at less 16 hours, and,
    d. filtration of the submicron liposomal formulation containing a mature saponin from step c. through a sterile quality filter.
    BE2017 / 5901
    In another aspect, the present invention provides a method of manufacturing a liposomal composition comprising a saponin in a submicron liposomal formulation in which the liposomes contain a lipid and a sterol, comprising the following steps:
    a) the maturation of a submicronic liposomal formulation containing a saponin in which the liposomes contain a lipid and a sterol for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, or at least 16 hours, and,
    b) filtration of the submicron liposomal formulation containing a mature saponin from step a) through a sterile quality filter.
    In another aspect, the invention provides a method for the preparation of a vaccine composition comprising the preparation of a liposomal composition according to the method described herein according to which the liposomal composition is combined with an antigen, either before or after filtration from step d. of the process.
    A method of preparing a vaccine kit comprising preparing a liposomal composition according to the method described herein and packaging the liposomal composition in a kit as a kit component in addition to a kit antigen component.
    Description of the figures
    Figure 1: Diagram illustrating the formulation of the liposomal formulation containing a saponin from Examples 2 and 3.
    Figure 2: Illustration of Vmax as a function of the time before filtration using different filters:
    BE2017 / 5901
    ♦ Sartopore 2 0.45 / 02; Sartopore 2 0, 35 / 0.2 ; at Sartopore 2 0.8 / 0.2; X Pall EKV; * Pali EDF. Figure 3: Illustration of the evolution of the size of particles (nm) of lot 1 (A) and lot 2 (B) of the formulation liposomal containing a saponin at different time to maturation for Example 3.
    Figure 4: Illustration of the evolution of the IPD of lot 1 (A) and lot 2 (B) of the liposomal formulation containing a saponin at different maturation times for Example 3.
    FIG. 5: Illustration of the Vmax on three different batches of filter of batch 1 (A) and batch 2 (B) of the liposomal formulation containing a saponin at different maturation times for example 3.
    Figure 6: Illustration of the cholesterol content (pg / ml) before and after filtration on three different lots of filters of lot 1 (A) and lot 2 (B) of the liposomal formulation containing a saponin at different maturation times for l 'example 3.
    Detailed description of the invention
    Liposomes, particularly submicron liposomes can be used in the formulation of immunological adjuvants.
    Vaccine compositions comprising said liposomes in combination with one or more antigens are usually administered parenterally and thus it is desirable that the liposomal compositions are sterile. The present inventors have surprisingly shown that a maturation step (as defined in the following section) solves / avoids the problems of filtration of the liposomes, such as clogging of the filter.
    Therefore, the present invention provides a method of making a composition comprising a saponin in a submicron liposomal formulation in which the liposomes contain a lipid and a sterol, comprising the
    BE2017 / 5901 following steps:
    at. the preparation of a first submicron liposomal formulation in which the liposomes contain a lipid and a sterol,
    b. adding saponin to the first submicron liposomal formulation, maturing the submicron liposomal formulation containing saponin for at least 1
    3,
    4, 5,
    6,
    9,
    10, 11,
    12, 13,
    14, 15, or, at least hours, and filtration of the submicron liposomal formulation containing a mature saponin from step c. through a sterile quality filter.
    Maturation
    By "maturation", it is meant that the submicron liposomal composition containing a saponrne is stored for at least 1, 2, 3,
    4, 5, 6, 7,
    9, 10, 11,
    12,
    13, 14,
    15, or at least 16 hours following the addition of the saponrne to the first liposomal submicron composition.
    In one embodiment, the maturation lasts for at least 4 hours, at least 6 hours or hours.
    In one embodiment, the ripening will be applied or carried out for no more than hours, no more, or, no more hours. In another embodiment, the maturation is applied for a time between 4 and 24 hours. In another embodiment, the maturation is applied or carried out for 16 to 24 hours. Maturation can be carried out in any suitable container. In one embodiment, the maturation is carried out without agitation of the formulation. After a formulation has undergone one or more
    BE2017 / 5901 maturation stages, it can be described as being "mature".
    Maturation is carried out at any suitable temperature. Generally, the maturation is carried out at room temperature, at a temperature between 15 and 30 ° C, or, at a temperature between 15 and 25 ° C. Alternatively, maturation is carried out at around 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 ° C.
    In one embodiment, the maturation is carried out at a temperature between 15 and 25 ° C for a period of 8 to 24 hours.
    Sterilization
    By "sterile quality filter" is meant a filter which produces a sterile effluent after being subjected to a test with micro-organisms at a test level greater than or equal to 1 x 10 7 / cm 2 of area of efficient filtration. Filters of sterile quality are well known to those skilled in the art of the invention and generally have a pore size of approximately 0.2 μm, and thus comprise filters with a pore size of approximately 0.22 μm . For the purpose of the present invention, the sterile quality filters have a pore size between 0.1 and 0.25 μm, as between 0.18 and 0.22 μm.
    The membranes of the sterile quality filter can be made of any suitable material known to those skilled in the art, for example, but not limited to, cellulose acetate, polyethersulfone (PES), polyvinylidene fluoride (PVDF) , polytetrafluoroethylene (PTFE), and the like. In a particular embodiment of the invention, one or more or all of the filter membranes of the present invention comprise polyethersulfone (PES), in particular hydrophilic polyethersulfone. In a particular embodiment of the invention, the filters used in the
    BE2017 / 5901 The methods described here are a double layer filter, in particular a sterile filter with an integrated prefilter having a larger pore size than the pore size of the final filter. In one embodiment, the sterilization filter is a double layer filter in which the layer of the prefilter membrane has a pore size between 0.3 and 0.5 μm, such as 0.35 or 0.45 μm . According to other embodiments, the filters include one or more asymmetric filter membranes, such as one or more asymmetric hydrophilic PES filter membranes. Alternatively, the sterilization filter layer can be made of PVDF, for example, in combination with a layer of asymmetric hydrophilic PES prefilter membrane.
    Liposomes
    The term "liposome" is well known in the art and defines a general category of vesicles which include one or more lipid bilayers surrounding an aqueous space. Liposomes thus consist of one or more lipids, such as phospholipid bilayers, and can contain other molecules, such as proteins and carbohydrates, in their structure. Because both lipid and aqueous phases are present, liposomes can encapsulate or trap water-soluble (water-soluble) material, lipid-soluble (liposoluble) material, and / or amphiphilic compounds. The liposomes provided for the present invention contain a significant amount of lipids (forming the liposomes). Liposomes forming liposomes are available in the art, and can be anionic, cationic or neutral lipids. In one embodiment, the portion of lipids forming liposomes consists essentially of neutral lipid. By "neutral lipid" it should be understood that the overall net charge of the lipid is (approximately)
    BE2017 / 5901 zero. Therefore, the lipid can be generally nonionic or it can be zwitterionic. In one embodiment, the liposomes include a zwitterionic lipid. Examples of suitable lipids are phospholipids such as phosphatidylcholine species. In one embodiment, the liposomes contain phosphatidylcholine as the liposome forming lipid which is suitably non-crystalline at room temperature. Examples of such non-crystalline phosphatidylcholine lipids include egg yolk phosphatidylcholine, dioleoylphosphatidylcholine (DOPC) or dilaurylphosphatidylcholine (DLPC). In a particular embodiment, the liposomes of the present invention contain DOPC, or, consist essentially of DOPC.
    Liposomes can also contain a limited amount of a charged lipid which increases the stability of the liposome-saponin structure for liposomes composed of saturated lipids, for example, lipids composed of DLPC. In these cases, the amount of loaded lipid is suitably from 1 to 20% w / w, preferably from 5 to 10% w / w of the liposomal composition. Suitable examples of such charged lipids include fatty acids such as lauric acid, or alternatively, phosphatidylglycerol and phosphatidylserine. Suitably, the neutral liposomes will contain less than 5% w / w of loaded lipid, such as less than 3% w / w or less than 1% w / w. In a particular embodiment, the liposomes are composed of DLPC and lauric acid, for example, in a DLPC / lauric acid ratio between 3.5 / 1 and 4.5 / 1, such as about 4/1.
    The liposomes provided for the present invention further comprise a sterol. Suitable sterols include ßsitosterol, stigmasterol, ergosterol, ergocalciferol and cholesterol. In a particular embodiment, the
    BE2017 / 5901 liposomes include cholesterol as a sterol. These sterols are well known in the art, for example cholesterol is disclosed in the Merck index, 11th Edn., Page 341, in the form of a naturally occurring sterol found in animal fat. The ratio of sterol to lipid is generally 1/100 to 1/2 (mol / mol), suitably 1/5 to 1/4, or about 1/4.
    In a specific embodiment, the liposomes of the present invention comprise DOPC and cholesterol in a ratio of 1/4 (cholesterol / DOPC).
    The mean diameter z (DMZ) and the polydispersity index (IPD) are determined on the basis of the data obtained by dynamic light scattering (DDL). A beam of monochromatic and coherent laser light illuminates a representative sample for the analysis of the size of the particles dispersed in a liquid at an appropriate concentration. The light scattered by the particles at a given angle is recorded by a detector (avalanche photodiode), the result of which is loaded into a correlator. Since the dispersed particles are in continuous Brownian motion, the observed scattered intensity fluctuates as a function of time. Consequently, the analysis as a function of time of these intensity fluctuations provides information on the movement of the dispersed particles. In a DDL experiment, the analysis over time is carried out with a correlator which builds the autocorrelation function over time of the scattered intensity. The degradation rate is linked to the translational diffusion coefficient D of the particles. This degradation is interpreted in terms of average particle size and polydispersity index by the process known as cumulants.
    For particles of spherical shape which do not interact and which are dispersed in a medium of viscosity η, the coefficient of
    BE2017 / 5901 diffusion D is associated with the hydrodynamic diameter of the DH particles by the Stokes-Einstein equation:
    kT
    3πηά Η where k is the Boltzmann constant,
    T the absolute temperature η the viscosity of the medium.
    The cumulants method is a simple method of analyzing the autocorrelation function produced by a DDL experiment. The calculation is defined in ISO 13321 and ISO 22412. The first two terms of this expansion in moments are used in practice, an average value for the size (size of average z or average z or diameter of average z), and a parameter of width known as the polydispersity index (IPD).
    Average size z
    The mean size z is a value calculated on the basis of intensity and should not be confused with or compared directly with a mean value by mass or number produced by other methods. The calculation is defined in ISO standards, so that all systems using this recommended calculation will have to give comparable results if the same beam angle is used.
    The mean size z or the mean z or the mean diameter z used in dynamic light scattering is a parameter also known as the mean of the cumulants. It is the primary and most stable parameter produced by the technique. The mean z is commonly used in a quality control configuration because it is defined in standard ISO 13321 and more recently ISO 22412 which defines this mean as the "average harmonic diameter weighted by the intensity of the particles".
    BE2017 / 5901
    The size of mean z will only be comparable to the size measured by other techniques if the sample is monomodal (that is to say, a single peak), of spherical or almost spherical size, monodispersed (i.e. i.e., very narrow distribution width), and if the sample is prepared in a suitable dispersant, since the mean size z may be sensitive to even minute changes in the sample, for example, the presence of a small proportion of aggregates. It should be noted that the mean z is a hydrodynamic parameter and that, therefore, it is only applicable to particles in a dispersion or to molecules in solution.
    Submicron liposomes have an average diameter of less than 1 μm. Methods for measuring the diameter of liposomes are well known to those skilled in the art, for example, dynamic light scattering. For the purpose of the description of the present invention, the mean diameter of the liposomes is expressed in mean diameter z (DMZ).
    The liposomes of the invention can have an average diameter between about 30 and 300 nm, between 50 and 225 nm, between 50 and 200 nm, between 80 and 200 nm, between 80 and 150 nm, or between 80 and 120 nm. Alternatively, the average diameter of the liposomes can be about 30, 40, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275 and 300 nm. In one embodiment, the liposomes produced by the methods of the invention have an average diameter between 50 and 150 nm. The average diameter of the liposomes can be affected, for example, by extruding the liposomal composition through sieves or meshes of a known pore size. These and other methods of controlling the size of liposomes are well known in the art and are described, for example, in Mayhew et al. (1984) Biochim. Brophys. Acta 775: 169-174 or Oison et al. (1979) Biochim. Brophys. Acta 557: 9-23. In a particular embodiment of the invention, the liposomes have an average diameter (DMZ) of less than approximately 220 nm, less than 200 nm, in particular between approximately 50 nm and approximately 150 nm, in particular between approximately 80 nm and 120 nm.
    BE2017 / 5901
    Polydispersity index
    This index is a number calculated from a simple 2-parameter adjustment to the correlation data (the cumulants analysis). The polydispersity index is dimensionless and on a scale of 0 to 1. Very small values (for example, 0.05) correspond to highly monodispersed standards. The closer the values are to 1, the wider the particle size distribution.
    The polydispersity index (IPD) of a liposomal formulation is a measure of the heterogeneity of the liposomal particles in the formulation. In one embodiment, the IPD of the liposomal formulation following the maturation of step c.
    is less than 0.225.
    In another embodiment,
    The IPD is less than 0.200.
    Saponins
    In the method of the invention, there is provided the step of adding a saponin to the liposomal formulation following the preparation of the submicronic liposomes and before the maturation step.
    A saponin particularly suitable for use in the present invention is Quil A and its derivatives. Quil A is a saponin preparation isolated from the South American tree Quillaja Saponaria Molina and was first described by Dalsgaard et al. in 1974 ("Saponin adjuvants", Archiv, für die gesamte Virusforschung, Vol. 44, Springer Verlag, Berlin, p 243-254) as having an adjuvant activity. Purified Quil A fragments which retain adjuvant activity without was isolated by HPLC
    BE2017 / 5901 the toxicity associated with Quil A (EP 0 362 279), for example QS7 and QS21 (also known as QA7 and QA21). QS21 is a natural saponin derived from the bark of Quillaja saponaria Molina, which induces CD8 + cytotoxic T lymphocytes (LTC), Thl cells and a predominant IgG2a antibody response and is a particular saponin in the context of the present invention.
    In particular, the saponins for use according to the present invention are immunologically active fractions of Quil A, such as QS-7 or QS21, suitably QS21. In a specific embodiment, QS21 is provided in its less reactogenic composition where it is neutralized by an exogenous sterol, such as cholesterol for example, which is incorporated into the liposomal formulation. The ratio of QS21 / sterol will generally be of the order of 1/100 to 1/1 (w / w), suitably between 1/10 and 1/1 (w / w), and preferably 1/5 to 1/1 (w / w). Suitably an excess of sterol is present, the ratio of QS21 / sterol being at least 1/2 (w / w). In one embodiment, the ratio of QS21 / sterol is 1/5 (w / w). The sterol is appropriately cholesterol.
    Stamps
    The liposomal formulation may contain a buffer. In addition, the method of the invention may include another step of adding buffer to the first liposomal formulation. The buffers used in the present invention include: a phosphate buffer (Na / Na2PO4, Na / K2PO4 or K / K2PO4); a Tris buffer; borate buffer; a succinate buffer; histidine buffer; or a citrate buffer. Buffers will generally be included in an amount between 5 and 20 mM. In a particular embodiment, the buffer is the phosphate buffer solution (PBS). The pH of the liquid mixture is adjusted in view of the therapeutic components of the composition.
    BE2017 / 5901
    Suitably, the pH of the liquid mixture is at least 4, at least 5, at least 5.5, at least 5.8, at least 6. In other words, the pH of the liquid mixture may be lower to 9, less than 8, less than 7.5 or less than 7. In other embodiments, the pH of the liquid mixture is between 4 and 9, between 5 and 8, between 5.5 and 7.5 , or, between 5.8 and 6.4. In a specific embodiment, the pH is about 6.1.
    Tone
    The solutions should have a pharmaceutically acceptable osmolality to avoid distortion or lysis of the cells. A pharmaceutically acceptable osmolality will generally mean that the solutions will have an osmolality which is approximately isotonic or slightly hypertonic. Suitably, the immunogenic compositions of the present invention will have an osmolality in the range of 250 to 750 mOsm / kg, for example, the osmolality may be in the range of 250 to 550 mOsm / kg, as in the range from 280 to 500 mOsm / kg. The osmolality can be measured according to techniques known in the art, such as by the use of a commercially available osmometer, for example Advanced® Model 2020 available from Advanced Instruments Inc. (United States).
    The tone of the composition can be adjusted using methods known to those skilled in the art such as by providing appropriate amounts of isotonic agents. An "isotonic agent" or "isotonic agent" is a compound which is physiologically tolerated and which communicates an appropriate tone to a formulation (for example, the immunogenic compositions of the invention) to prevent the net flow of water to the through cell membranes that are in contact with the formulation. Known aqueous compositions of adjuvants which contain 100 mM or more of chloride
    BE2017 / 5901 sodium, for example the adjuvant system A (ASA) in documents WO 2005/112991 and WO 2008/142133 or the liposomal adjuvants disclosed in document WO 2007/068907.
    In certain embodiments, the isotonicity agent used for the composition is a salt, such as sodium chloride. However, in other embodiments, the composition comprises a nonionic isotonic agent and the concentration of sodium chloride or the ionic strength in the composition is less than 100 mM, such as less than 80 mM, for example, less at 30 mM, as less than 10 mM or less than 5 mM. The composition can comprise a nonionic isotonic agent and the conductivity of the composition is less than 5 mS / cm, as less than 4 mS / cm. In a preferred embodiment, the nonionic isotonicity agent is a polyol, such as sorbitol. The concentration of sorbitol can be, for example, between about 3% and about 15% (w / v), such as between about 4% and about 10% (w / v). Adjuvants comprising an immunologically active saponin fraction and a TLR4 agonist where the isotonicity agent is a salt or a polyol have been described in documents WO 2012/080369 and WO 2012/080370.
    Preparation of the submicron liposomal composition
    Methods for preparing the first submicron liposomal formulation of step a. are available in document WO 2013/041572 (also published under the reference US 20140234403, incorporated herein by reference in its entirety), in particular Examples 3 and 4, describe methods for the manufacture of a liposomal preparation of DOPC liposomes containing cholesterol and possibly 3D-MPL. The liposomal preparation as described in this reference is also mixed with QS21.
    BE2017 / 5901
    In one embodiment, the liposomes obtained in step a. have been subjected to homogenization, or in other words, step a. includes homogenization of the liposomal formulation, in particular high shear and / or high pressure homogenization.
    In another embodiment, step a. is carried out using a method for forming a lipid film comprising the steps of (i) dissolving a mixture of lipids in a solvent to form a homogeneous mixture; (ii) removing the solvent to form a lipid film (for example, by evaporation); (iii) hydration of the lipid film with a hydrating solution to form a liposomal composition; and (iv) reducing the size of the liposome to form a submicron liposomal composition (in particular using high shear and / or high pressure homogenization).
    Homogenization
    In one embodiment of the invention, the liposomes are first pre-homogenized with a high shear mixer. This step is supposed to reduce the size of the coarse liposomes. A rotor or turbine, together with a stationary component known as a stator, or a set of rotors and stators, is used either in a tank containing the solution to be mixed, or in a pipe through which the solution passes, to create a shear. A high shear mixer can be used to create emulsions, suspensions, lyosols (gases dispersed in a liquid) and granular products.
    In one embodiment, the pre-homogenized liposomes are further homogenized with a high pressure homogenizer. This process is well known in the art and usually involves a conventional homogenizer. The solution may be
    BE2017 / 5901 homogenized in the first reaction vessel or the solution can be transferred to a second reaction vessel before homogenization. Reaction vessels suitable for use as a second reaction vessel may contain a volume of liquid and include, but are not limited to, vessels, such as stainless steel vessels, flasks or beakers. In one embodiment, the suspension of the liposomes is pressurized during homogenization.
    In one embodiment, the liposomes are homogenized using a high shear inline homogenizer with a high pressure homogenizer. Such technology is well known in the art and homogenization usually occurs in a pressure range between 5,000 and 30,000 psi, i.e., 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or 30,000 psi.
    TLR-4 Agonist
    In another embodiment, the liposomal formulation further comprises a TLR-4 agonist. For example, this can be a detoxified lipopolysaccharide. The lipopolysaccharide acts as an immunostimulant in liposomes produced using the methods of the invention. In one embodiment, the lipopolysaccharide is a non-toxic derivative of lipid A, such as monophosphoryl-lipid A or more particularly monophosphoryl-lipid A 3-deacylated (3D-MPL). 3D-MPL is sold as MPL by GlaxoSmithKline Biologicals S.A. and is referred to throughout the document MPL or 3D-MPL. See, for example, US patents
    No. 4,436,727; 4,877,611; 4,866,034 and 4,912,094. 3D-MPL
    BE2017 / 5901 mainly promotes responses in CD4 + T lymphocytes with an IFN-7 phenotype (Thl).
    3D-MPL can be produced according to the methods disclosed in document GB 2220211 A. From the chemical point of view, it is a mixture of monophosphoryl-lipid A 3-deacylated with
    3, 4, 5 or 6 acylated chains. Mixtures containing more than 20% of 6 acylated chains are preferred. In the compositions of the present invention, small particle 3D-MPL can be used. The small particle 3D-MPL has a particle size such that it can be sterilized by filtration through a sterilization filter such as one of the sterilization filters described for the purpose of the invention. Such preparations are described in document WO 94/21292.
    Other TLR-4 agonists that can be used are alkyl glucosaminide phosphates (AGP) such as those disclosed in WO 98/50399 or US Patent No. 6,303,347 (methods for the preparation of AGP are also disclosed), appropriately RC527 or RC529 or pharmaceutically acceptable salts of AGP as disclosed in US Patent No. 6,764,840. Some AGPs are TLR- agonists
    4, and some are antagonists of TLR-4. Both are believed to be useful as adjuvants.
    Other suitable TLR-4 ligands are as described in documents WO 2003/011223 and WO 2003/099195, such as compound I, compound II and compound III described on pages 4-5 of document WO 2003 / 011223 or on pages 3—4 of document WO 2003/099195 and in particular these compounds described in document WO 2003/011223 as ER803022, ER803058, ER803732, ER804053, ER804057m ER804058, ER804059, ER804442, ER804680 and ER804764. For example, a suitable ligand for ΤΕΕΙ is ER804057.
    Other TLR-4 ligands which can be used in the present invention include the lipid builder
    BE2017 / 5901 glucopyranosyle (GLA) as described in documents WO 2008/153541 or WO 2009/143457 or the articles in the literature Coler RN et al. (2011) Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant. PLoS ONE 6 (1): el6333. doi: 10.1371 / journal. pone .0016333 and Arias MA et al. (2012) Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIV gpl40. PLoS ONE 7 (7): e41144. doi: 10.1371 / journal.pone .0041144. Documents WO 2008/153541 or WO 2009/143457 are incorporated here by reference with the aim of defining ligands for TLR-4 which can be used in the present invention.
    A TLR-4 ligand such as a lipopolysaccharide, such as 3D-MPL, can be used in amounts between 1 and 100 µg per human dose of the adjuvant composition. 3DMPL can be used at a rate of approximately 50 pg, such as at least 40 pg, at least 45 pg or at least 49 pg, or, less than 100 pg, less than 80 pg, less than 60 pg, less than 55 pg or less than 51 pg. Examples of suitable ranges are between 40 and 60 pg, suitably between 45 and 55 pg or between 49 and 51 pg or 50 pg. In another embodiment, the human dose of the adjuvant composition comprises
    3D-MPL at a rate of approximately pg, such as at least 20 pg, at least at least pg or at least 24 pg, or, less than ug.
    less than pg, less than 27 g or less than pg.
    Examples of lower ranges include between and 30 pg, suitably between 21 and pg or between 22 and between 24 and pg, or 25 pg.
    BE2017 / 5901
    Conditioning
    Following sterilization by filtration, the sterile submicron liposomal composition is packaged in suitable containers. The submicronic liposomal compositions can be packaged in vials, in particular single-dose glass vials. As a variant, the submicronic liposomal compositions can be packaged in bags such as storage bags made of high density polyethylene.
    Vaccine preparation processes
    The present invention further provides methods for preparing vaccines comprising preparing a submicron liposomal composition by the methods of the invention described herein and by combining the liposomal composition with an antigen.
    The term "antigen" is well known to those skilled in the art.
    An antigen can be a protein, polysaccharide, peptide, nucleic acid, protein polysaccharide conjugates, a molecule or a hapten that is capable of producing an immune response in a human or animal. Antigens can be derived, homologous, or synthesized to mimic molecules from viruses, bacteria, parasites, protozoa, or fungi. In a variant embodiment of the invention, the antigen is derived, homologous or synthesized to mimic molecules originating from a tumor cell or from a neoplasia. In another embodiment of the invention, the antigen is derived, homologous or synthesized to mimic molecules originating from a substance involved in allergy, Alzheimer's disease, atherosclerosis, obesity and nicotine addiction.
    In a particular embodiment of the invention, the antigen is derived from Plasmodium spp., For example, P. falciparum or P. vivax.
    In a particular embodiment of the invention, the antigen is derived from Mycobacterium spp., For example,
    M. tuberculosis.
    BE2017 / 5901
    Possible antigens derived from Plasmodium falciparum include circumsporozoite protein (CS protein), RTS,
    PfEMP-I, the Pfs 16 antigen, MSP-I, MSP-3, LSA-I, LSA-3, AMA-I and TRAP. Other P. falciparum antigens include EBA, GLURP, RAP1, RAP2, sequestrin, Pf332, STARP, SALSA, PfEXPI, Pfs25, Pfs28, PFS27 / 25, Pfs48 / 45, Pfs230 and their analogs in other Plasmodium spp . The antigen can be a whole protein or one of its immunogenic fragments.
    An antigen derived from the CS protein of Plasmodium falciparum may be in the form of a hybrid fusion protein. The fusion protein may contain a protein derived from the CS protein of P. falciparum fused to another protein or to one of its fragments. The fusion protein may contain an N-terminal or C-terminal fragment derived from the protein
    CS of P. falciparum. Alternatively, or in addition, the fusion protein may comprise one or more repeating units (e.g., 1, 2, 3,
    4, 5, 6, repeating units the central region of the CS protein of P. falciparum. In one embodiment, the fusion protein is a hybrid fusion protein comprising an antigen derived from the CS protein together with a surface antigen from hepatitis B (Ag HBs) or one of its immunogenic fragments. Generally, the surface antigen from hepatitis B includes the major surface protein known as the S antigen, for example, the S antigen derived from an adw serotype.
    In particular, the fusion protein can comprise substantially all of the C-terminal part of the P. falciparum CS protein, four or more tandem repeats of the immunodominant region of the CS protein, and the surface antigen
    BE2017 / 5901 aspect, the fusion protein comprises a sequence which contains at least 160 amino acids which is substantially homologous to the C-terminal part of the CS protein. In particular, "substantially all" the part
    C-terminal of the CS protein comprises the end
    Terminal without the hydrophobic anchoring sequence.
    The CS protein can be devoid of the last 12 to 14 (like 12) amino acids from the C-terminus.
    In one embodiment, the fusion protein for use in the invention is a protein that includes part of the protein
    CS of
    P.
    falciparum corresponding substantially to amino acids
    207 to 395 of the 3D7 clone of
    P. falciparum, derived from the NF54 strain (Caspers et al., Above) fused in the frame via a linear linker to the N-terminal part of Ag HBs. The linker can include part or all of the preS2 region from HBsAg.
    A particular fusion protein for use in the invention is the fusion protein known as
    RTS, as described in WO documents
    93/10152 and
    WO 98/05355. The
    RTS can be in the form of mixed particles RTS, S (where “represents an unfused monomer) or in the form of
    RTS. The RTS, S particles comprise two polypeptides
    RTS and S which can be synthesized simultaneously and which spontaneously form composite particulate structures (RTS, S), for example, during purification.
    These particles can also be called pseudoviral particles (PPV). Such particles can be prepared in a number of ways, for example, by expressing the fusion protein in a suitable host such as yeast or bacteria.
    The presence of surface antigen from hepatitis B and the formation of RTS, S particles are thought to stimulate
    BE2017 / 5901
    The immunogenicity of the CS protein portion of the hybrid protein, aid in stability, and / or assist in the reproducible manufacture of the protein.
    The CS antigens can be used in conjunction with another antigen chosen from any antigen which is expressed on the sporozoite or at the pre-erythrocytic stage of the parasite life cycle such as the hepatic stage, for example, the hepatic stage 1 antigen ( LSA-1), hepatic stage 3 antigen (LSA-3), an anonymous protein associated with thrombospondin (TRAP), merozoite surface protein 1 (MSP1), the major merozoite surface protein, and apical antigen 1 of merozoite (AMA-1). Other antigens suitable for use in conjunction with CS antigens include PfEMP-I, Pfs 16 antigen, MSP-3, LSA-3, AMA-I, TRAP, GLURP, RAP1, RAP2, sequestrin, Pf332, STARP , SALSA, PfEXPI, Pfs25, Pfs28, PFS27 / 25, Pfs48 / 45, Pfs230.
    The immunogenic fragments of any of the antigens as described herein will contain at least one epitope of the antigen and exhibit malaria antigenicity and will be able to produce an immune response when presented in an appropriate construct such as, for example , when fused to other malarial antigens or other non-malarial antigens, or presented on a support, the immune response being directed against the native antigen. Generally, the immunogenic fragments contain at least 20, or at least 50, or at least 100 contiguous amino acids originating from the malarial antigen.
    Antigens from P. vivax include antigens based on the circumsporozoite protein (CS protein) and the Duffy antigen binding protein and its fragments, such as PvRII (see, for example, WO 02/12292).
    CS protein-based antigens include a fusion protein comprising sequences derived from a
    BE2017 / 5901 CS protein of P. vivax. In one embodiment, the fusion protein is a hybrid fusion protein. The hybrid protein here may contain a protein derived from P. vivax type I and type II. In particular, the hybrid fusion protein may contain a protein derived from P. vivax type I and type II fused to another protein or to one of its fragments.
    In one aspect, the hybrid fusion protein comprises a hybrid protein derived from the P. vivax CS proteins (CSV) and a surface antigen from hepatitis B, generally the major surface protein known as an antigen S, such as the S antigen derived from an adw serotype.
    Preferably, the fusion protein is an immunogenic hybrid fusion protein comprising: a) at least one repeating unit derived from the central repeat section of a circumsporozoite protein of P. vivax type I, b) at least one repeating unit derived from the central repeat section of a circumsporozoite protein from P. vivax type II, and
    c) the surface antigen S derived from the hepatitis B virus.
    The CSV-derived antigen component according to the invention is generally fused to the amino-terminal end of protein S. More specifically, the C-terminal end of the CSV fragment is fused to the N-terminal end of said antigen S. For example, a suitable fusion protein is CSV-S, as described in WO 2008/009652.
    In yeast cells, once expressed, the hybrid fusion protein (including the S antigen) is capable of spontaneously assembling into a lipoprotein / particle structure composed of numerous monomers of said proteins (or PPV). Such particles can be prepared by expressing the fusion protein in a suitable host such as yeast or bacteria.
    When the chosen recipient yeast strain also carries in its genome one or more integrated copies of a hepatitis B S expression cassette, the resulting strain synthesizes the hybrid protein in the form of fusion proteins, and also the antigen S not fused.
    These can spontaneously assemble into lipoprotein particles comprising monomers of the fusion protein
    BE2017 / 5901 hybrid and S antigen monomers
    There is also provided a PPV comprising units of
    CSV-S and / or RTS. The particle can consist essentially of CSV-S units and
    RTS.
    Alternatively, the particles produced comprise or consist essentially of units
    CSV-S, RTS and S.
    Such mixed particles are described, for example, in the document
    Antigens of interest in the field of tuberculosis include Mtb72f and its variants, as disclosed in WO 2006/117240. An antigen of particular interest is M72, whose polypeptide sequence is provided by SEQ ID NO: 4 and a polynucleotide sequence coding for said polypeptide being provided by SEQ ID NO: 3 of document WO 2006/117240.
    Another antigen of interest in the field of tuberculosis is Rvl753 and its variants, as disclosed in document WO 2010/010180, for example, a sequence of Rvl753 chosen from SEQ ID NO: 1 and 2 to 7 from document WO 2010/010180, in particular SEQ ID NO: 1. Another antigen of interest in the field of tuberculosis is Rv2386 and its variants, as disclosed in document WO 2010/010179, for example, a sequence of Rv2386 chosen from SEQ ID NO: 1 and 2 to 7 of document WO 2010/010179, in particular SEQ ID NO: 1. Other antigens of interest in the field of tuberculosis include Rv3616 and its variants, as disclosed in document WO 2011092253, for example a natural sequence of Rv3616 chosen from SEQ ID NO: 1 and 2 to 7 of the document
    BE2017 / 5901
    WO 2011/092253 or a modified sequence of Rv3616 such as those chosen from SEQ ID NO: 161 to 169, 179 and 180 of document WO 2011092253, in particular SEQ ID NO: 167. An antigen of additional interest is HBHA, such as disclosed in documents WO 97/044463, WO 03/044048 and WO 2010/149657.
    The tuberculosis antigens are suitably used in the form of a polypeptide, but alternatively they can be provided in the form of a polynucleotide encoding said polypeptide.
    In a particular embodiment, the methods of the invention use antigens derived from the varicella zoster virus (VZV). The VZV antigen for use in the invention may be any suitable VZV antigen or one of its immunogenic derivatives, suitably being a purified VZV antigen. The term "immunogenic derivative" encompasses any molecule which retains the ability to induce an immune response against VZV following administration to humans.
    Processes suitable for the production of derivatives are well known in the art and include conventional molecular biology techniques as disclosed, for example, in Sambrook et al. [Molecular Cloning: A Laboratory Manual, third edition, 2000, Cold Spring Harbor Laboratory Press], such as techniques for the addition, deletion, substitution or rearrangement of amino acids or chemical modifications of these. In one aspect, the derivatives include, for example, truncations or other fragments.
    In one aspect, the derivatives according to the invention are amino acid sequences comprising epitopes, that is to say, antigenic determinants substantially responsible for the immunogenic properties of a polypeptide and capable of triggering an immune response, being in one aspect of T cell epitopes
    BE2017 / 5901
    In one aspect, the level of immunogenic activity of the immunogenic derivative is at least about 50%, in one aspect of at least about 70% and in one aspect of at least or greater than about 90% of the immunogenicity for the polypeptide from which it is derived, appropriately estimated by the immunological techniques described above. In certain aspects of the invention, immunogenic parts can be identified which exhibit a higher level of immunogenic activity than that of the corresponding full-length polypeptide, for example, having more than approximately 100% or
    150% or more of immunogenic activity. In one aspect, the VZV antigen is a glycoprotein, in one (also known as gpl), or its aspects the immunogenic derivative gE antigen.
    The gE antigen, its non-anchoring derivatives (which are also immunogenic derivatives) and their production are described in document EP 0405867 and the references which it cites [see also Vafai A. Antibody binding sites on truncated forms of varicella-zoster gpl virus (gE) glycoprotein Vaccine 1994 12: 1265-9]. EP 192902 also discloses gE and its production.
    In one aspect, the gE is a truncated gE having the sequence of SEQ ID NO: 1 as disclosed in Virus research, vol 40, 1996 pl99 ff, incorporated herein by reference in its entirety. The reference to gE below includes the reference to truncated gE, unless deducted otherwise according to the context.
    Ki ts
    The present invention also provides methods for the preparation of a vaccine kit comprising the preparation of submicronic liposomal compositions of the invention and the packaging of the liposomal composition in a kit as
    BE2017 / 5901 as a kit component in addition to an antigen component of
    The antigen and / or liposomes can be prepared extemporaneously at the time of administration. Thus, the invention provides methods for the preparation of vaccine kits comprising an antigen and a liposomal composition ready for mixing.
    The kits allow the antigen and the liposomal composition to be stored separately until the time of
    Use.
    The components are physically separated from each other in a kit, and this separation can be achieved in various ways. For example, the two components can be in two separate containers, such as vials. The contents of the two vials can then be mixed, for example, by removing the contents of one vial and adding it to the other vial, or by removing the contents of the two vials separately and mixing them in a third container ( for example, a bottle).
    In a particular embodiment, one of the components of the kit is in a syringe and the other is in a container such as a vial. The syringe can be used (for example, with a needle) to insert its contents into the second container for mixing, and the mixture can then be drawn into the syringe. The mixed contents of the syringe can then be administered to a patient, usually using a new sterile needle. Packaging a component in a syringe eliminates the need to use a separate syringe for administration to the patient. In another preferred embodiment, the two components of the kit are packaged together but separately in the same syringe, for example, a double chamber syringe. When the syringe is activated (for example, during administration to a patient) then the contents of the two chambers are mixed. This embodiment avoids the need for a separate mixing step at
    BE2017 / 5901 time of use.
    The components of the kit can be in aqueous form.
    liposomal) is under
    In some modes lyophilized form),
    of production, a component (such as a dry form (by example, under a and the other component (the composition form aqueous. The of them components can
    dry component and give to be mixed in order to reactivate an aqueous composition for administration to a patient. A lyophilized component will usually be located in a vial rather than a syringe.
    The dried components can include stabilizers such as lactose, sucrose or mannitol, as well as mixtures thereof, for example, lactose / sucrose mixtures, sucrose / mannitol mixtures, etc. One possible embodiment uses an aqueous adjuvant component in a pre-filled syringe and a lyophilized antigen component in a vial.
    The embodiments relating to "vaccine compositions" of
    The invention are also applicable to embodiments relating to immunogenic compositions of the invention, and vice versa.
    The singular terms "a", "an", "the" or "the include articles in the plural unless the context clearly indicates otherwise. Similarly, the word "or" is expected to include "and" unless the context clearly indicates otherwise. The term "plurality" refers to two or more.
    The term "includes" means "includes
    Thus, unless the context requires otherwise, the word includes "and variations such as" includes "and including" will be understood to imply the inclusion of a compound or composition (eg, nucleic acid, polypeptide, or antigen) or a step indicated, or a group of compounds or steps, but not the exclusion of any other compound,
    BE2017 / 5901 composition, stage or group thereof. The abbreviation “e.g.” is derived from the Latin exempli gratia, and is used here to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example”. The open transitional sentences "comprising", "include" and "includes" here are intended by the inventors to be optionally substituted by the closed transitional sentences "consisting of", "consist of" and "consists of", respectively, in all cases.
    In addition, the numerical limitations given with respect to temperatures, percentages, concentrations, or rates of a substance, such as a composition, are approximate.
    Thus, when a temperature is indicated as being 15 ° C to 25 ° C, it is expected that the temperature will be understood to be approximately (or "" or ° C to approximately (or ° C.) , a concentration is indicated as being at least (for it is intended that the concentration is understood to be at least approximately (or “” or approximately ”in relation to a numerical value x signifies x ±
    Although methods and materials similar or equivalent to those described herein may be used in the practice or analysis of this disclosure, suitable methods and materials are described below. The following examples illustrate the invention.
    Examples
    Example 1. Preparation of the concentrated liposomal mass
    The concentrated liposomal mass was prepared as described in Example 3 of document WO 2013/041572 (incorporated herein by reference in its entirety). In short, the mass
    BE2017 / 5901 concentrated liposomal was prepared in 2 steps. The first step was the preparation of a lipid film. DOPC (dioleoyl-phosphatidylcholine), 3D-MPL and cholesterol were dissolved sequentially in isopropanol. Then the isopropanol was removed with stirring and reduced pressure gradient in a heating bath at 55 ° C to obtain a film residue. The pressure was then gradually reduced and final drying was applied to obtain a lipid film. The second step was the preparation of the concentrated liposomal mass. For this purpose, the lipid film was rehydrated in PBS to form a coarse suspension of liposomes. The liposome suspension was then homogenized with a high shear mixer in line with a high pressure homogenizer to produce the desired liposomes with a size on the order of a nanometer. The resulting concentrated liposomal mass (which does not include QS21) is filtered through a 0.22 μm PES membrane. The concentrated liposomal mass for use in the examples contained 40 mg / ml DOPC, 10 mg / ml cholesterol, 2 mg / ml MPL in 10 mM phosphate buffer (pH 6.1) and 150 mM NaCl.
    Example 2. Preparation ____ of____ liposomes____ containing____ saponin - Filterability
    The objective of the test was to assess the filterability of the liposomal formulation containing QS21 after different maturation times (0 hours, 1/2 hour, 4 hours and 24 hours) and on different filters (Sartopore 2 0.45 -0.2 μm, Sartopore 2 XLI 0.35-0.2 μm, Sartopore XLG 0.8-0.2 μm, Pall EKV and Pali EDF). The liposomal formulation is prepared by following the protocol illustrated by the diagram in FIG. 1. In summary, the addition of QS21 to the concentrated liposomal mass as prepared in Example 1, in an appropriate buffer, results in the liposomal formulation containing QS21 to be submitted for filterability assessment, as described above.
    the liposomal formulation used for the following composition:
    MPL
    100 pg / ml
    Cholesterol
    500 pg / ml
    DOPC
    QS21
    NaCl
    Na 2 HPO 4
    KH2PO4
    2000 pg / ml
    100
    150
    2.1
    7, 9
    Filterability pg / ml mM mM mM was tested at
    BE2017 / 5901
    For the present test, the filtration had measured by the Vmax, to have passed through, that is to say, the maximum volume which the filter can filter before the filter is blocked. The results obtained are listed in Table 1 and illustrated in Figure 2.
    Table 1
    Time before filtration (maturation time) Filter type Vmax (ml / cm 2 ) 0 hour Sartopore 2 0.45-0.2 μ 31.2 Sartopore 2 XLI 0.35-0.2 μ 22.8 Sartopore XLG 0.8-0.2 μ 19, 6 Pall EKV 33.3 V2 hour Sartopore 2 0.45-0.2 μ 37.8 Sartopore 2 XLI 0.35-0.2 μ 29, 1 4 hours Sartopore 2 0.45-0.2 μ 60.1 Sartopore 2 XLI 0.35-0.2 μ 52.3 Sartopore XLG 0.8-0.2 μ 45.4
    BE2017 / 5901
    Pali EKV 0.65-0.2 μ 76, 4 Sartopore 2 0.45-0.2 μ 62.2 Sartopore 2 XLI 0.35-0.2 μ 52, 9 Sartopore XLG 0.8-0.2 μ 42 24 hours Sartopore 2 0.45-0.2 μ 76.5 Sartopore 2 XLI 0.35-0.2 μ 88.7 Sartopore XLG 0.8-0.2 μ 62.7 Pali EKV 107 Pali EDF 87.3
    Results
    Regardless of the type of filter used, the filterability of the liposomal composition containing QS21 increases with the maturation time, as shown by the increase in Vmax according to the maturation time. The longer the maturation of the liposomes, the higher the Vmax.
    Example 3. Preparation ____ of ____ liposomes____ containing ____ saponin - Particle size, IPD, Vmax, MPL / QS21 / DOPC / cholesterol content
    Two batches of liposomal formulation containing QS21 having the composition as detailed for example 2, were also produced following the diagram in FIG. 1. Three batches of Pall EKV filters (Pall 1, Pall 2 and Pall 3) were been tested, without maturation (T0) and after 2 or 4 hours of maturation (T2H and T4H). The following parameters were measured:
    - average particle size (nm) before and after maturation (DMZ)
    - IPD before and after maturation
    - Vmax (ml / m 2 ) during filtration
    BE2017 / 5901
    - MPL, QS21, DOPC and cholesterol content before and after filtration
    The MDZ and IPD were measured in accordance with ISO 13321 and ISO 22412 standards.
    Table 2 lists the indicated contents measured at T0,
    T2H and T4H after filtration on the different batches of Pall EKV filters. A sample was also collected before filtration to be used as the reference content.
    Table 2
    Lot 1 Maturation time(T) - Filter set(Pall No.) MPL(pg / ml) QS21(pg / ml) DOPC(mg / ml) Cholesterol(pg / ml) before filtration 107 105 2 503 TO Vmax 1 - Pall 1 106 102 2 490 T2H Vmax 1 - Pall 1 105 102 2 495 T4H Vmax 1 - Pall 1 105 103 2 496 TO Vmax 2 - Pall 2 108 100 2 491 T2H Vmax 2 - Pall 2 104 103 2 500 T4H Vmax 2 - Pall 2 107 104 2 499 TO Vmax 3 - Pall 3 104 100 1.9 484 T2H Vmax 3 - Pall 3 107 102 2 499 T4H Vmax 3 - Pall 3 106 103 2 502 Lot 2 Maturation time(T) - Filter set(Pall No.) MPL(pg / ml) QS21(pg / ml) DOPC(mg / ml) Cholesterol(pg / ml) before filtration 90 112 2 500 TO Vmax 1 - Pall 1 86 104 2 483 T2H Vmax 1 - Pall 1 87 107 2 496 T4H Vmax 1 - Pall 1 93 108 2 494
    BE2017 / 5901
    TO Vmax 2 - Pali 2 88 106 2 490 T2H Vmax 2 - Pali 2 96 108 2 491 T4H Vmax 2 - Pali 2 103 110 2 four hundred ninety seven TO Vmax 3 - Pall 3 85 106 2 483 T2H Vmax 3 - Pall 3 92 108 2 489 T4H Vmax 3 - Pall 3 102 109 2 492
    Results
    Regardless of the filter batch, with the two batches of liposomal formulations containing QS21, there is no significant variation in the contents measured after a maturation time of 2 h or 4 h (and after filtration), compared to contents measured before filtration. This indicates that there was no loss of content with respect to MPL, QS21, DOPC and cholesterol after maturation.
    Results for particle size (Figure 3), IPD (Figure 4), Vmax (Figure 5) and cholesterol content (Figure 6) are shown in Figures 3 to 6. Figure 3 (3A and 3B) shows that the size of the liposomes increases with the time of maturation. Figure 4 (4A and 4B) shows that, in parallel, the polydispersity (IPD) decreases with the maturation time because the smaller liposomes disappear. Without wishing to be bound by a theory, it is believed that the filterability is improved after the maturation of the liposomes containing QS21 (as is shown again in FIGS. 5A and 5B, in which the Vmax increases with the maturation time) because , in the absence of the maturation step, smaller liposomes are present and can gradually accumulate in the pores of the filter and eventually lead to clogging of the filter.
    BE2017 / 5901
    SEQ ID NO: 1
    MGTWKPVVG VLMGFGHTG TEPITNPVRA 8VLRYDDFHI DEDKLDTNSV YEPYYHSDHA
    TJ F.SS.A'NPGF- SRhXYDH'JSi i NPPKL1YDC LLENAHEHHG VYKijCpriDS ΰΠΡΙ v 2r'TQF 121 gAßEDLGDDT GIHVT.PTLNG DDBRKl'VNVD QRQYGDVFKG DLNPKPQGQR L1EVSVBENH 181 PFTLP.AF.ICR IYGVRYTETW 3FLPSLTCTG DAAPAIQHIC LKHTTCFQDV WDVÖCAENT .241 KEDQLAEISY P.FQGKKEAÖC PWIVVNTSTL EDELELDPPE IEPGVLKVLR TEKQYLGVYT 301 WNMRGSDGTS TYATFLVTWK GDEKTRNPTP AVTPQPRGAE FHMWNÏHSHV FSVGDTFSX.A 361 MHLQYKIHEA PFDLLLEW1.Y VPIDPTCQPM RLYSTCLYHP NAPQCLSHMN SGCTFTSPHL 421 AQRVASIVÏQ NCEHADRYTA YCLGISHMEP SFGLILHDGG TTLKFVDTPE SLSGLYVFVV 4SI Î 1-2.:-./AV h A ƒ rv ^ TVDHF VNATFRRGFl TTAGQPPATT KPKEITPVb " G13PL1RYAA 541 VÏTGGLA
    BE2017 / 5901
    权利要求:
    Claims (7)
    [1]
    1. Method for manufacturing a liposomal composition comprising a saponin in a submicron liposomal formulation in which the liposomes contain a lipid and a sterol, comprising the steps of:
    a) preparation of a first submicron liposomal formulation in which the liposomes contain a lipid and a sterol,
    b) addition of saponin to the first liposomal submicronic formulation,
    c) maturation of the submicron liposomal formulation containing a saponin for at least 1, 2, 3, 4, 5,
    6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or, 4 p.m., and,
    d) filtration of the submicron liposomal formulation containing a mature saponin from step c) through a sterile quality filter.
    [2]
    2. The method of claim 1, wherein the first submicron liposomal formulation further contains a TLR-4 agonist.
    [3]
    3. Method according to any one of the preceding claims, in which the lipid is a neutral lipid.
    [4]
    4. The method of claim 3, wherein the neutral lipid is a phosphatidylcholine selected from egg phosphatidylcholine, dioleoyl-phosphatidylcholine (DOPC) or dilauryl-phosphatidylcholine.
    [5]
    5. Method according to any one of the preceding claims, in which the neutral lipid is DOPC.
    [6]
    6. Method according to any one of the preceding claims, in which the sterol is cholesterol.
    BE2017 / 5901
    7. Process according to any one the lipid ratio about 4/1. ofsure claimssterol is located previous, between 3/1 and in which5/1, like < 8. Method according to any one of claims previous, in which saponin is the QS21. 9. Process according to any one of claims previous, in which the agonist of TLR-4 is a
    lipopolysaccharide.
    10. Process according to any of claims previous, in which the agonist of TLR-4 is 3D-MPL. 11. Process according to any of claims
    above, in which the liposomal formulation is buffered at a pH between 5 and 7, as at 6.1.
    12. Method according to any one of the preceding claims, in which the liposomes following the filtration of step d) have a mean diameter z between 80 and 120 nm.
    13. Method according to any one of the preceding claims, further comprising step e) of filtration of the submicron liposomal formulation of step d) through another sterile quality filter.
    14. Method according to any one of the preceding claims, in which the method further comprises a step of adding buffer to the submicron liposomal formulation of step a).
    BE2017 / 5901
    15. Method according to any one of the preceding claims, in which the filtration of step d) is carried out at a temperature between 15 and 25 ° C.
    16. Method according to any one of the preceding claims, in which the maturation of step c) is carried out at a temperature below 15 ° C as between 2 and 8 ° C, and, the filtration of step d) is carried out at a temperature between 15 and 25 ° C.
    17. Method according to any one of claims 1 to 15, in which the maturation of step c) and the filtration of step d) are carried out at a temperature between 15 and 25 ° C.
    18. Method according to any one of the preceding claims, in which the maturation is carried out for at least 6 hours.
    19. Method according to any one of the preceding claims, in which the maturation is carried out for not more than 48 hours, not more than 36 hours, or not more than 24 hours.
    20. Method according to any one of the preceding claims, in which the maturation is carried out for 16 to 24 hours.
    21. Method according to any one of claims 1 to 19, in which the maturation is carried out at a temperature between 15 and 25 ° C for 8 to 24 hours.
    BE2017 / 5901
    22. Method according to any one of the preceding claims, in which the filtration is carried out at a pressure between 1 and 1.5 bar.
    23. Method according to any one of the preceding claims, in which the polydispersity index (IPD) of the submicron liposomal formulation containing a saponin after maturation in step c) is less than 0.225, or less than 0.200.
    24. Method according to any one of the preceding claims, in which the, or at least one sterile quality filter is a double layer filter, the first layer of which has a larger pore size than the filter of the second layer.
    25. Method according to any one of the preceding claims, in which the filtered composition is packaged in glass bottles or sterile bags.
    26. A method for the preparation of a vaccine composition comprising the method according to any one of claims 1 to 25 and the combination of the filtered composition with an antigen.
    27. The method of claim 26, wherein the vaccine is used in the prevention, alleviation or treatment of malaria, shingles, chronic obstructive pulmonary disease (COPD), CMV infection, RSV infection in the elderly, HBV infection, HIV infection, tuberculosis (TB), HSV infection, HPV infection, staphylococcus , C. difficile, community acquired pneumonia (CAP).
    BE2017 / 5901
    28. A method of preparing a vaccine kit comprising preparing the liposomal composition according to any of claims 1 to 25 and packaging the liposomal composition in a kit as a kit component in addition to a component kit antigen.
    29. Method according to claim the antigen is lyophilized in a bottle and the liposomal composition is in a serrngue.
    30. A method of manufacturing a liposomal composition comprising a saponin in a submicron liposomal formulation in which the liposomes contain a lipid and a sterol, comprising the steps of
    a) maturation of a submicron liposomal formulation containing a saponin in which the liposomes contain a lipid and a sterol for at least 1, at least 2, at least 3, at least 4, at least 5, at least
    6, at least
    [7]
    7, at least 9, at least 10, at least 11, at least
    12, at least
    13, at least 14, at least
    15, or at least 16 hours, and,
    b) filtration of the submicron liposomal formulation containing a mature saponin from step a) through a sterile quality filter.
    31. The method of claim 30, wherein the maturation of step a) is applied for 16 to 24 hours.
    类似技术:
    公开号 | 公开日 | 专利标题
    KR100357804B1|2004-06-14|Particulate matter-containing glass polysomes, preparation methods thereof and liposome preparations containing them
    JP2002522397A|2002-07-23|Vaccine containing ISCOM consisting of sterol and saponin without other surfactants
    BE1022346A9|2016-10-07|LIPOSOMAL COMPOSITIONS FOR MUCOSAL ADMINISTRATION
    EP0831780B1|2006-03-29|Improved liposomal formulation
    FR3066920A1|2018-12-07|NOVEL METHODS OF MANUFACTURING AN ADJUVANT
    BE1024188B1|2017-12-14|DRY COMPOSITION
    BE1025160B1|2018-11-26|NEW PROCESS
    BE1024094B1|2017-11-16|VACCINE
    BE1025119B1|2018-11-05|NOVEL METHODS FOR INDUCING AN IMMUNE RESPONSE
    EP1024830B1|2004-11-24|Antigen vectors in the form of multilamellar vesicles
    EP3886901A1|2021-10-06|Methods for manufacturing an adjuvant
    BE1022373B1|2016-03-25|NEW ANTIMALARIAL VACCINES
    Kersten et al.2004|Liposomes and ISCOMS
    BE1024160B9|2017-12-06|IMMUNOGENIC FORMULATION
    WO2006059009A1|2006-06-08|Novel pharmaceutical composition useful for vaccines
    FR2802422A1|2001-06-22|Structured mixed phase of liquid crystal and biological macromolecule, are useful for delivering nucleic acids for gene therapy, based on amphiphilic compounds
    WO2004073596A2|2004-09-02|Vaccine composition comprising an hiv proteic antigen incorporated into multilamellar lipidic vesicles
    FR2868951A1|2005-10-21|Preparation of homogeneous mixture, useful in preparing composition containing vesicles, involves preparing aqueous solution containing active ingredients, dispersing amphiphilic agent and eliminating water
    同族专利:
    公开号 | 公开日
    JP2020500891A|2020-01-16|
    US10695424B2|2020-06-30|
    CN110035770A|2019-07-19|
    CA3045952A1|2018-06-14|
    US20200061186A1|2020-02-27|
    EP3551222A1|2019-10-16|
    MX2019006728A|2019-12-02|
    WO2018104313A1|2018-06-14|
    BE1025160A1|2018-11-20|
    BR112019011286A2|2019-10-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO1998015287A1|1996-10-05|1998-04-16|Smithkline Beecham Biologicals S.A.|Vaccines|
    WO2000007621A2|1998-08-05|2000-02-17|Smithkline Beecham Biologicals S.A.|Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent|
    WO2005112991A2|2004-05-21|2005-12-01|Glaxosmithkline Biologicals Sa|Vaccines|
    WO2010142686A1|2009-06-10|2010-12-16|Glaxosmithkline Biologicals S.A.|Immunogenic compositions having low sodium chloride concentration|
    WO2013041572A1|2011-09-20|2013-03-28|Glaxosmithkline Biologicals S.A.|Liposome production using isopropanol|
    US4436727A|1982-05-26|1984-03-13|Ribi Immunochem Research, Inc.|Refined detoxified endotoxin product|
    US4866034A|1982-05-26|1989-09-12|Ribi Immunochem Research Inc.|Refined detoxified endotoxin|
    US4769239A|1984-08-21|1988-09-06|Merck & Co., Inc.|Vaccine against varicella-zoster virus|
    US4877611A|1986-04-15|1989-10-31|Ribi Immunochem Research Inc.|Vaccine containing tumor antigens and adjuvants|
    CA1331443C|1987-05-29|1994-08-16|Charlotte A. Kensil|Saponin adjuvant|
    US4912094B1|1988-06-29|1994-02-15|Ribi Immunochem Research Inc.|Modified lipopolysaccharides and process of preparation|
    CY1933A|1989-06-27|1990-06-22|Smithkline Biolog|Novel compounds|
    JP3954643B2|1991-11-16|2007-08-08|グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム|Hybrid protein between CS and HBsAG derived from Plasmodium|
    EP0812593B8|1993-03-23|2010-11-10|SmithKline Beecham Biologicals S.A.|Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a|
    FR2748748B1|1996-05-17|1998-11-06|Pasteur Institut|IDENTIFICATION AND CLONING OF A MYCOBACTERIAL ANTIGEN CORRESPONDING TO A HEPARIN BINDING HEMAGGLUTIN|
    GB9616351D0|1996-08-02|1996-09-11|Smithkline Beecham Biolog|Vaccine composition|
    US6113918A|1997-05-08|2000-09-05|Ribi Immunochem Research, Inc.|Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors|
    US6764840B2|1997-05-08|2004-07-20|Corixa Corporation|Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors|
    US6303347B1|1997-05-08|2001-10-16|Corixa Corporation|Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors|
    US6551600B2|1999-02-01|2003-04-22|Eisai Co., Ltd.|Immunological adjuvant compounds compositions and methods of use thereof|
    US20040006242A1|1999-02-01|2004-01-08|Hawkins Lynn D.|Immunomodulatory compounds and method of use thereof|
    GB0019375D0|2000-08-07|2000-09-27|Int Centre Genetic Eng & Bio|Method of polypeptide renaturation|
    FR2832410B1|2001-11-19|2004-04-02|Pasteur Institut|RECOMBINANT MYCOBACTERIAL ANTIGEN OF HEMAGGLUTININ TYPE OF METHYLATED HEPARIN BINDING, METHODS OF PREPARATION AND IMMUNOGENIC COMPOSITIONS COMPRISING SUCH ANTIGEN|
    CN101273055B|2005-04-29|2016-03-16|葛兰素史密丝克莱恩生物有限公司|For preventing or treat the novel method of m tuberculosis infection|
    TWI457133B|2005-12-13|2014-10-21|Glaxosmithkline Biolog Sa|Novel composition|
    EA018201B1|2007-05-24|2013-06-28|Глаксосмитклайн Байолоджикалс С.А.|Lyophilised antigen composition|
    US9592282B2|2006-07-18|2017-03-14|Glaxosmithkline Biologicals Sa|Vaccines for malaria|
    SI2068918T1|2006-09-26|2012-09-28|Infectious Disease Res Inst|Vaccine composition containing synthetic adjuvant|
    US20090181078A1|2006-09-26|2009-07-16|Infectious Disease Research Institute|Vaccine composition containing synthetic adjuvant|
    ES2685498T3|2008-07-25|2018-10-09|Glaxosmithkline Biologicals S.A.|Rv2386c tuberculosis protein, compositions and uses thereof|
    SG10201505149WA|2008-07-25|2015-07-30|Glaxosmithkline Biolog Sa|Novel compositions and methods|
    WO2010149657A1|2009-06-22|2010-12-29|Px Therapeutics|Method for the purification of hbha|
    AU2011209399B2|2010-01-27|2014-04-10|Glaxo Group Limited|Modified tuberculosis antigens|
    EA027504B1|2010-12-14|2017-08-31|Глаксосмитклайн Байолоджикалс С.А.|Mycobacterium antigenic composition|WO2020055503A1|2018-09-14|2020-03-19|Massachusetts Institute Of Technology|Nanoparticle vaccine adjuvant and methods of use thereof|
    法律状态:
    2018-12-17| FG| Patent granted|Effective date: 20181126 |
    优先权:
    申请号 | 申请日 | 专利标题
    GB1620758.1|2016-12-07|
    GBGB1620758.1A|GB201620758D0|2016-12-07|2016-12-07|Novel process|
    GBGB1708734.7A|GB201708734D0|2017-06-01|2017-06-01|Novel process|
    [返回顶部]